VANCOUVER, BC — Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical‐stage natural psychedelic drug development company, and Jupiter Acquisition Corporation (NASDAQ:JAQC) (“Jupiter”), a special purpose acquisition… Read More
Gardiner will oversee talent acquisition and HR operations during period of rapid company growth VANCOUVER, BC — Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, today… Read More
Pravibismane is the first of a new class of drugs with broad-spectrum potency against a wide range of pathogens, including NTM species Poster presentation highlighted the results from pravibismane in… Read More
OTTAWA, ON | Health Canada Today, the Honourable Mark Holland, Minister of Health, announced a new appointment to the Patented Medicine Prices Review Board (PMPRB). Following a merit-based selection process,… Read More
Nimbus Synergies, a leading Canadian early-stage health technology investor and mentor to Canada’s most promising health tech entrepreneurs, is excited to announce the GENERATOR’s relocation to new office space situated… Read More
